Sarah, senior associate in our Life Sciences Health Industry Group, focuses her practice on health care anti-corruption, regulatory, and litigation matters. Sarah counsels life sciences clients (including medical device and pharmaceutical companies, DMEPOS suppliers, hospitals, retail pharmacy chains, and universities) on a wide variety of fraud and abuse matters, including responding to state and federal government investigations, conducting internal investigations, and defending against qui tam and whistleblower lawsuits under the federal False Claims Act. In addition, she also has experience with federal congressional investigations related to the health care industry and has represented clients in responding to multiple subpoenas issued by the U.S. House Oversight and Government Reform Committee in a high profile investigation.
Sarah has also designed and implemented corporate compliance programs at clients of varying sizes, including companies on the precipice of launching a new product for the first time. She regularly reviews, revises, and audits clients' policies and procedures for compliance and best practices. Sarah is often asked to train clients and other attorneys on matters including the U.S. Open Payments / Sunshine Act, Stark Law, Anti-Kickback Statute, and Foreign Corrupt Practices Act.
Sarah's area of expertise also extends to state, federal, and international transparency and disclosure laws, which often require life sciences companies to report the payments and other transfers of value they make to health care professionals and other entities. She has advised clients regarding not only the U.S. Sunshine Act and similar state laws, but she also works closely with global colleagues to advise clients regarding the constantly-changing international landscape, including laws such as the French Loi Bertrand and Belgian Sunshine Law, as well as relevant industry codes, such as MedTech Europe.
